European Medicines Agency recommends granting a marketing authorisation for ponatinib

The European Medicines Agency Committee for Medicinal Products for Human Use has adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product ponatinib (Iclusig) 15 mg and 45 mg film-coated tablets intended for the treatment of chronic myeloid leukaemia and Philadelphia chromosome positive acute lymphoblastic leukaemia. Read more here.